Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Apollomics Inc C Met Apl 101 Sparta 2 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Details on the Phase 1/2 SPARTA global clinical trial can ... in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met ... Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
In the 71 treatment-naïve NSCLC patients with Met Exon 14 skipping mutation (36 from SPARTA and 35 from KUNPENG), the objective response rate (ORR) was 66.2 ... Apollomics’ lead ... Read More
Apollomics, Inc. (APLM)
April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics ... global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non ... Read More
China’s NMPA grants conditional approval for Apollomics’ NSCLC drug
Velbretinib (APL-101) is an orally bioavailable small molecule that treats NSCLC patients with MET exon 14 skipping alterations by inhibiting c-Met ... October 31 press release, Apollomics ... Read More
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics is conducting a multi-cohort Phase 2 study of vebreltinib, SPARTA, at over 90 ... programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of ... Read More
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
Apollomics Inc ... (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 ... Read More
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Details on the Phase 1/2 SPARTA global clinical ... stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of ... Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment ... https://www.apollomics.com. This press release includes statements that ... Read More
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/c-MET axis ... Read More
Apollomics Inc.: Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China ... Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq ... with Met Exon 14 skipping mutation (36 from SPARTA and 35 from KUNPENG), the objective response rate (ORR) was 66.2% (95% confidence ... Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus